We are live on ! Find out more
RDHL

Redhill Biopharma
RDHL

22 hedge funds and large institutions have $21.2M invested in Redhill Biopharma in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

5% more funds holding

Funds holding: 21 → 22 (+1)

31% less capital invested

Capital invested by funds: $30.5M → $21.2M (-$9.32M)

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

Holders
22
Holders Change
+1
Holders Change %
+4.76%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ISL
Ingalls & Snyder LLC
New York
+$486K
2
OC
Oppenheimer & Co
New York
+$150K
3
TRCT
Tower Research Capital (TRC)
New York
+$11.6K
4
VanEck Associates
VanEck Associates
New York
+$11.6K

Top Sellers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
-$6.13M
2
BC
Broadfin Capital
New York
-$937K
3
SM
Sabby Management
Florida
-$104K
4
Morgan Stanley
Morgan Stanley
New York
-$57.8K
5
Deutsche Bank
Deutsche Bank
Germany
-$11.6K

RDHL Hedge Fund Activity: Q2 2016 in Review

22 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q2 2016, worth a combined $21.2M — down 31% from $30.5M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new RDHL positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 5 trimmed.

The largest buyer was Ingalls & Snyder LLC, opening a new position worth an estimated $486K. The largest seller was Visium Asset Management, exiting entirely with an estimated $6.13M sold.

  • 22 institutional investors held Redhill Biopharma (RDHL) as of Q2 2016, up from 21 in Q1 2016.
  • Funds reported $21.2M of Redhill Biopharma stock for Q2 2016, down 31% quarter-over-quarter.
  • 3 funds opened new Redhill Biopharma positions in Q2 2016 and 2 closed out, a net change of +1 holder.
  • The largest Redhill Biopharma buyer in Q2 2016 was Ingalls & Snyder LLC, an estimated $486K added.
  • The largest Redhill Biopharma seller in Q2 2016 was Visium Asset Management, an estimated $6.13M sold.

Based on aggregated 13F filings for Q2 2016.